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Salvage surgery is a feasible and potentially curative treatment in patients with isolated 
recurrent or persistent EC after definitive CRT or when surgery was deferred or omitted after 
neoadjuvant CRT. Major pulmonary and cardiovascular complications were less frequent 
after salvage esophagectomy among patients with recurrent disease compared to those with 


















Background: Isolated local recurrent or persistent esophageal cancer (EC) after curative 
intended definitive (dCRT) or neoadjuvant chemoradiotherapy (nCRT) with initially omitted 
surgery, is a potential indication for salvage surgery. We aimed to evaluate safety and efficacy 
of salvage surgery in these patients.  
Material and methods: A systematic literature search following PRISMA guidelines was 
performed using databases of PubMed/Medline. All included studies were performed in 
patients after initial treatment with dCRT or nCRT, between 2007 and 2017. Survival analysis 
was performed with an inverse-variance weighting method. 
Results: Of the 278 identified studies, 28 were eligible, including a total of 1076 patients. 
Postoperative complications after salvage esophagectomy were significantly more common 
among patients with isolated persistent than in those with locoregional recurrent EC, 
including respiratory (36.6% versus 22.7%; difference in proportion 10.9 with 95% 
confidence interval (CI) [3.1; 18.7]) and cardiovascular complications (10.4% versus 4.5%; 
difference in proportion 5.9 with 95% CI [1.5; 10.2]). The pooled estimated 30- and 90-day 
mortality was 2.6 % [1.6; 3.6] and 8.0% [6.3; 9.8], respectively. The pooled estimated 3-year 
and 5-year overall survival (OS) were 39.0 % (95% CI: [35.8; 42.2]) and 19.4% [95% 
CI:16.5; 22.4], respectively. Patients with isolated persistent or recurrent EC after initial CRT 
had similar 5-year OS (14.0% versus 19.7%, difference in proportion -5.7, 95% CI [-13.7; 
2.3]).  
Conclusions: Salvage surgery is a potentially curative procedure in patients with locally 
recurrent or persistent esophageal cancer and can be performed safely after definitive or 























1.1 INTRODUCTION  
Only half of the patients with esophageal cancer (EC) present with potentially curable disease 
[1]. At present, neo-adjuvant chemoradiotherapy (nCRT) followed by esophagectomy is 
standard care in patients with curative resectable locally advanced EC. Generally, nCRT 
induces downsizing and downstaging of the primary tumor and may sterilize involved lymph 
nodes. This improves locoregional control, while decreasing the risk of distant metastasis [2-
4]. As established in the CROSS (Chemoradiotherapy for Oesophageal Cancer followed by 
Surgery Study) regimen, nCRT also increases the 5-year survival with 13% compared to 
surgery alone [2]. This was accompanied by a high rate of microscopic radical (R0) resection 
(92%) with an overall pathologic complete response (pCR) rate of 29%. Absence of vital 
cancer cells at pathological examination more often occurred in esophageal squamous cell 
carcinoma (49%) than in adenocarcinoma (23%) [3, 5-9]. Given the risk of perioperative 
morbidity and mortality, it is questionable whether esophagectomy is needed in all patients 
after nCRT, while it remains difficult to appropriate select patients who may not need the 
additional surgery [3]. On the other hand, when patient’s current physical health is sufficient 
salvage surgery may even be performed in local recurrent EC after nCRT, if the presumed 
surgery has been deferred or omitted [3,5-9].  
Moreover, definitive chemoradiotherapy (dCRT) is generally a good alternative curative 
treatment in patients above the age of 75 years with severe co-morbidities or those who are 
unfit for surgery [10, 11]. Local failure after dCRT can present as local recurrent of persistent 
disease, which occurs in nearly 50% of the patients [5-8, 12]. Salvage surgery as an attempt to 
cure these patients that could be offered to a subgroup of patients when non-surgical treatment 
has failed [2]. The variation in the rate of salvage surgery with curative intent after dCRT (4% 
to 29%) and the reported 5-year overall survival (OS) of 0-33% stress the need for a better 
selection [8-9,13,14]. Moreover, the downside of salvage surgery after dCRT is the rather 
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high rate of perioperative complications including anastomotic leakage, pneumonia with 
respiratory insufficiency and sepsis. This may impact on hospital stay, prolonged intensive 
care treatment, perioperative mortality and health-related quality of life [10].  
The aim of this systematic review is to determine whether salvage surgery can be safely 
performed in patients with localized solitary recurrent or persistent disease after dCRT or 

















2.1.1 Search strategy and study selection 
A systematic literature search was performed using databases of PubMed/Medline 
(https://www.ncbi.nlm.nih.gov/pubmed) to retrieve all relevant studies with the following 
keywords ‘esophageal cancer’ and additive with the medical subject headings (MesH) 
database terms ‘esophageal neoplasms’, ‘salvage surgery’, ‘salvage esophagectomy’ and 
‘rescue esophagectomy’. This review was conducted according to the Preferred Reporting 
Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines [14]. Reference lists 
and reviews were additionally screened for relevant papers. Relevant published studies were 
selected based on the best available evidence in the period January 2007 - July 2017. The 
starting year 2007 was chosen because in that period dCRT was a standardized treatment 
option and positron emission/computed tomographic (PET/CT) imaging was introduced as a 
standard diagnostic modality. All included studies were peer-reviewed and published in the 
last ten years. Duplicate publications or articles for which the full text was not available in 
English, or studies without PET/CT in the routine staging were excluded. Two reviewers 
independently assessed the methodological quality of each study by reviewing the full text. 
Disagreement between was resolved by discussing the paper and if necessary in consensus 
with the senior researcher.  
2.1.2 Eligibility criteria and definitions  
Studies were eligible if the reported analyses also included treatment-related mortality, 
complications, and survival after salvage surgery for regrowth persistent or recurrent localized 
EC after CRT. For this review, the common definitions were used. Salvage esophagectomy, 
designated as salvage surgery in this study, was defined as esophagectomy with curative 
intent for resectable locoregional recurrent or persistent tumor in a previously irradiated area. 
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Generally, salvage esophagectomy is possible when an isolated local regrowth is clinically 
suspected after dCRT or nCRT without subsequent planned surgery. Persistent EC was 
defined as a still curable localized tumor ≤ 3 months after completion of CRT, that was still 
present either on endoscopic or radiologic examination (CT or PET/CT), and preferably 
confirmed cyto/histologically. Recurrent EC was defined as a regrowth at the primary site 
and/or regional area > 3 months after completion of CRT with initial clinical complete 
response (cCR) [15,16]. Radicality of resections was designated as R0, when both 
longitudinal and lateral resection margins were microscopically tumor free or as R1 when 
incomplete (< 1 mm), and as R2 in case of macroscopic residual tumor. 
2.1.3 Data collection processes and definition, clinical end–point and study selection 
Titles and abstracts were screened, and data, including first author, year of publication, 
sample size, patient and tumor characteristics (age, sex, co-morbidity, physical status, stage of 
tumor, staging modality, histology (esophageal squamous cell carcinoma: ESCC or 
esophageal adenocarcinoma: EAC), prior initial treatment dCRT or nCRT, and survival 
(overall and disease-free) were extracted from relevant studies using a predefined form.  
Primary outcomes were treatment-related morbidities and mortality (safety), defined as death 
caused by peri-operative complications associated with salvage surgery and postoperative 
mortality was defined as 30-day or 90-day mortality after salvage surgery. Pulmonary 
complications were pneumonia, atelectasis, or hypoxia that required re-intubation. 
Cardiovascular complications included myocardial infarction, dysrhythmias, cardiac failure, 
and stroke. Secondary outcomes were overall survival (OS) defined as the time from the date 
of salvage surgery until date of death from any cause, or end of follow-up. As only 2 studies 
described disease-free survival (DFS) we decided to evaluate OS alone.  
The quality of the individual studies was assessed using the Newcastle-Ottawa Scale (NOS) 
score for risk of bias developed as an assessment tool for non-randomized studies in meta-
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analyses or systematic reviews (http://www.ohri.ca/programs/clinical epidemiology/oxford. 
asp), which has been validated in other systematic reviews. The NOS score for cohort studies 
contains eight items that focus on the following three aspects depending on study type: 
selection, comparability, and outcome. The risk of bias assessment, including low, medium 
and high risk was performed by two independent reviewers.  
2.1.4 Follow-up 
In most studies (N=24), the minimal follow-up consisted of CT thorax/abdomen , every 3 
months during the first year and every 6 months thereafter, to detect tumor re-growth. The 
more recently reported follow-up studies also added periodic PET or PET-CT to rule out 
metastatic disease. Based on the detected suspicious lesions further examination i.e 
EUS/cytological and/or histological examination was performed. 
2.1.5 Statistical analysis  
Continuous variables were expressed as mean or median and range. Categorical variables 
were expressed as number and percentage. We assessed estimates and standard errors of 
overall survival (OS) using the fixed-effects inverse variance-weighting (IVW) approach, and 
of mortality and complications using proportions and standard errors. The fixed effects model 
assumes that the included studies share a single true effect size, whereas IVW summarizes 
effect sizes from multiple independent studies by calculating the weighted mean of the effect 
sizes using the inverse variance of individual studies, as weights. The 95%-confidence 
intervals for the differences between the group proportions were calculated.  Statistical 
analyses were performed with IBM SPSS Statistics for Windows, Version 23.0 (Armonk, 





3.1 RESULTS  
3.1.1 Study population  
In this systematic review 28 of the 278 identified studies, including 1076 patients were 
eligible for further analyses (Figure 1). Twenty-five studies included only patients treated 
with dCRT and 2 studies reported on patients after nCRT who underwent delayed surgery. In 
one study, salvage esophagectomy was performed in patients after both dCRT (N=10; mean 
54.7 Gy) and nCRT (N=2; mean 42.7 Gy) [17]. These twelve patients were only included in 
the whole group analyses (Figure 1 and Table 1).  
The majority of patients were males (88.1%) and the mean age was 62.4 (range 50.9-73.9) 
years in the dCRT and 62.5 (range 49.5-75.5) years in the nCRT group (Table 1). Most 
patients had an ESCC (76.7%) and had stage III disease (52.5%). The indication for surgery, 
i.e. persistent or recurrent disease, was unknown in 73.6%. Persistent or recurrent disease was 
reported in 17.5% and 8.9%, respectively. A radical (R0) resection was achieved in 80.7% of 
the patients, which was higher after dCRT compared to nCRT (Table 1).    
3.1.2 Surgery after dCRT and nCRT  
Salvage resections were more frequently reported after dCRT, including 3 studies with 
isolated locoregional recurrent (LR) EC, 4 studies with persistent and 18 studies with 
recurrent or persistent EC (Table 2a). In the dCRT-setting, chemotherapy consisted of 5- 
fluorouracil (5-FU) plus cisplatin and/or taxane (N=21) or was not reported (N=4). The 
median radiotherapy dose was 57.0 (range 30-62.5) Gy.  
Only two studies reported delayed surgery after > 6 months in patients after nCRT for 
regrowth during a wait and see approach after refusing the initially planned surgical 
procedure (Table 2b). Taketa et al. showed the outcome of salvage resection in patients with 
12 
 
LR disease after declining primary surgery because of cCR, whereas Piessen et al. reported 
the results of persistent EC in non-complete responders after initially nCRT. The median time 
to salvage resection were 9.3 and 14.3 months, respectively (Table 2b) [17-20].  
3.1.3 Morbidity and mortality      
Pulmonary complications were seen in 29.3% of patients, anastomotic leak in 17.2%, and 
cardiovascular complications in 6.7% of the patients (Table 3). In patients treated with 
salvage surgery after dCRT, pulmonary disorders, anastomotic leaks, infections and 
cardiovascular complications occurred in 30.2%, 18.6%, 12.5% and 7.6%, respectively (Table 
4).  
The overall 30- and 90-day mortality were 2.6% and 8.0 %, respectively. The estimated 30-
day mortality was similar for patients with both type of regrowth (1.7%) and comparable in 
both the primary dCRT and nCRT groups (Table 3 and 4). The estimated 90-day mortality 
was slightly lower after nCRT versus dCRT (3.1% versus 8.8%) and after recurrent disease 
(3.7% versus 7.3%) versus persistent tumor. 
3.1.4 Efficacy: overall survival 
The pooled 3- and 5-year OS were 39.0% and 19.4%, respectively. Patients with R0 resection 
had a higher 3- and 5-year OS of 48.8% and 25.6%, respectively. The 3-and 5-year OS were 
not statistically significant different following salvage surgery for persistent and recurrent EC 
(Table 3). Patients treated with salvage surgery after dCRT had a pooled 3-year OS of 38.7% 
and a pooled 5-year OS of 24.1%. After nCRT, which was performed only in two studies, the 







This systematic review shows that salvage surgery is feasible and potentially curative in a 
selective group of EC patients with locoregional regrowth (residual or recurrent) after initial 
treatment with dCRT or nCRT not followed by surgery. The novelty of this review is that we 
reported the commonly presented complications i.e. respiratory and cardiovascular 
complications with the impact among EC patients after salvage esophagectomy in both 
isolated recurrent and persistent disease after dCRT and nCRT when surgery was initially 
omitted for > 3 months.  
As shown in Table 3 and 4, salvage esophagectomy following dCRT is also associated with a 
high rate of anastomotic leak (17.2%-18.6%). This relatively high rate of anastomotic leak 
may be related to the common high doses of radiotherapy (50.4-60Gy) and a subsequently 
reduced microcirculation and conduit perfusion with even areas of patchy necrosis, especially 
after unintended surgical micro-injuries [15]. Although correlated with a high incidence of 
postoperative morbidity, salvage surgery can be performed with acceptable risks in selected 
patients with isolated locoregional failure. In a subset of these patients, the outcome seems 
even comparable to the results of patients who underwent planned surgery as reported in some 
studies (Table 5a/b) [3,5, 21-23]. Moreover, salvage surgery with curative intent may offer a 
significant survival benefit with a 5-year OS rate of 35% and 5-year DFS rate of 21% [5-8; 
24]. After initial curative treatment, approximately 50-75% of the EC patients develop 
recurrent disease usually within the first two to three years after treatment (75-98%) [6,12, 
25]. Nearly 19 to 25% are isolated locoregional recurrences (LR’s) which are more often seen 
after dCRT [26-28].  
Although salvage resection is a potential option, the surgical management of LR’s or 
persistent remnants after dCRT remains controversial for several reasons. Most salvage 
procedures are performed in SCC (76.7%) compared to 23.3% with EAC (Table 1). The study 
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of Marks et.al. [16] is the only one that described salvage surgery after failed dCRT in 
patients with EAC into more detail. The incidence of major event (35%), including major 
pulmonary complications (23.1%) and anastomotic leak (18.5%), 30-day mortality (3.1%) and 
3-year overall survival (48%) were comparable with patients after planned resection. The 
results were more or less comparable with those after dCRT in all patients in this review 
(Table 3 and 4) suggesting that salvage esophagectomy also should be considered in recurrent 
EAC after CRT.  
Another issue is the timing of salvage esophagectomy, which generally depends upon the time 
of diagnosis of regrowth isolated recurrences or persistent disease. This stresses the 
importance of follow-up schedules. Moreover timing of surgery is directly associated with 
patients condition and severe comorbidities. Exact timing is therefore difficult to give. Of 
great importance is whether the resection will be radical (R0) as shown on preoperative PET-
CT and preferably combined with magnetic resonance imaging (MRI) and EUS [15, 
16,29,30,31, 32, 33,34]. As in this review, Sudo et al. stressed the importance of R0 resection 
in salvage surgery with a median OS of 58.6 months compared to 9.5 months when surgery 
was refused. Besides the achievement of complete R0 resection after salvage surgery, the 
presence of early (cT2/N0) recurrent EC is the most favorable prognostic factor in patients 
with isolated regrowth after dCRT [9, 35]. Also in clinical non-responders with still surgically 
curable residual disease, Stahl et al. found a 3-year survival rate of 32% in those with a R0 
resection vs. 9.4% after the initial dCRT [11]. Recently, Swisher et al. described even more 
encouraging long-term survival rates in clinical non-responders, with a 5- and 7-year survival 
of 41% and 35%, respectively [32].  
These results stress the importance of better locoregional control through improved 
chemoradiation strategies in dCRT (combined cisplatin/5-FU or paclitaxel/carboplatin) and 
adequate staging with sophisticated imaging methods to ensure complete salvage resection 
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with an increased probability of R0 resection [32, 36]. Moreover, to select candidates for 
surgery with curative intent, a standard surveillance protocol should be used during the first 2-
3 years after initial dCRT in localized tumors [2, 9, 28,35].  
Currently there are no widely accepted follow-up protocols for early detection of LR’s, which 
might result in a better outcome after salvage resection. A recently proposed follow up 
scheme by the RTOG 0246 consists of serial endoscopies with ultrasound (EUS), CT scans or 
PET-CTs every 3 months twice and every 6 months three times for the first 2 years, and 
yearly thereafter. The results should be discussed in a specialized multidisciplinary team and 
could eventually result in salvage surgery in patients with isolated recurrent or persistent 
cancer [23].  
Depending on follow-up strategies, approximately one-third of these patients may eventually 
benefit or able to undergo a salvage resection [28]. However, in the detection of persistent 
disease the accuracy of restaging by EUS remains limited due to obliterated fibrous tissue 
planes [32, 33, 37, 38,39]. Whereas, both 18F-FDG-PET/CT and the more recently applied 
diffuse weighted magnetic resonance imaging (DWI-MRI) seem to be promising in the post-
CRT setting [32, 33,34].   
Surgery more than 3 months after dCRT is challenging due to difficulties in the dissection of 
friable and obliterated fibrous tissue planes with healing disorders and increased local 
complications based on hypovascularity and microvasculature injuries. If performed for 
regrowth in recurrent or persistent EC, it may lead to poorer local disease control, as was 
observed in the R0 resection rate of 80.7% (range 30-100) in Table 3. It is obvious that 
selection bias plays a role, as salvage resection is the only chance of cure in patients with 
potentially resectable recurrent and persistent EC, especially if the probability of R0 resection 
is disputable (in  cT3 tumors). This is reflected in the reported lower percentages of 




The performance of salvage surgery and even the initial choice of treatment is frequently 
limited by poor condition due to coexisting severe co-morbidities in a subgroup of patients 
with isolated LR EC. As shown in this study, pulmonary and cardiovascular complications 
often occur after salvage esophagectomy in patients with regrowth of persistent EC, probably 
due to earlier surgery in biologically more aggressive tumors with inadequate response after 
dCRT [9, 25, 32,41-43]. Since salvage surgery after dCRT is more challenging to perform 
than surgery after nCRT, complications develop more frequently after dCRT. In previous 
irradiated mediastinal tissues salvage surgery commonly carries substantial morbidity with 
increased blood transfusion, length of surgery, IC and hospital stay and overall mortality 
compared with standard surgical resection after nCRT [5, 6, 15,44].  This is not surprisingly, 
as the given radiation dose is commonly higher (50.4 to 60 Gy) with subsequently more 
fibrotic tissues, hampering adequate identification and dissection of recurrent tumor mass [2, 
25, 15]. In the study of Markar et al. patients who had salvage surgery after a total radiation 
dose >55 Gy revealed a significant increase of in-hospital mortality (27.8% v 4.3%) and 
overall morbidity (75.9% v 61%) compared with those who received <55 Gy [15]. Moreover, 
it was accompanied by a higher rate of anastomotic leaks (27.8% vs. 15%), surgical infections 
(29.6% vs. 16.1%), and pulmonary complications (55.6% vs. 40.2%). However, in our study 
the pooled 30-day mortality and 90 day-mortality after surgery were comparable with the 
postoperative mortality in patients after nCRT and planned surgery (2.8% and 8.1% vs. 2-4% 
vs. 5-10%) [ 3, 4,21, 22, 45,46].  With this in mind the performance of salvage 
esophagectomy should be well considered in patients with isolated persistent EC after dCRT. 
This procedure can be performed depending on the grade of preexistent respiratory, and 
cardiovascular co-morbidities. To prevent the common cardiopulmonary related 
complications pre, peri and postoperative measures should be taken into account.  
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More recent studies showed that postoperative pulmonary complications also have a great 
impact on overall survival [47-49]. Several factors may decrease the associated risk of 
morbidity and mortality after salvage resection. The use of modern radiotherapy techniques, 
like modulated radiation therapy and or volumetric arc therapy (IMRT/VMAT) may decrease 
the risk of cardiac and pulmonary toxicities by lowering the radiation dose to normal tissue 
during the initial treatment (Table 2c) [51-52]. In the near future, proton radiotherapy allows 
an even larger reduction of the dose to normal tissues [53]. In addition, lower toxic profiles of 
new chemotherapeutic schemes contribute to decrease these complications [50, 51,54]. 
However, one of the most important factors in lowering the risk of morbidity and mortality, is 
the concentration of salvage and delayed surgery in specialized high-volume centers. 
Although the operative approach is commonly not described into detail in most reported 
articles, salvage esophagectomy should be performed only when potential curability is 
achievable, preferably with wide margins through a transthoracic approach with two-field 
lymphadenectomy and cervical anastomosis. Meticulous preserving of the gastroepiploic 
vascularization and if possible even the right gastric artery may avoid conduit necrosis with 
subsequent anastomotic leak. Moreover, specialized centers have the disposal of special 
adaptive surgical techniques, including a two-staged procedure with retrosternal gastric tube 
reconstruction and the use of long-pedicle omental flaps or colon interposition occasionally 
even with cervical microvascular anastomosis when the viability of the stomach is disputable. 
Moreover, caution should be taken to preserve bronchial arteries in preventing trachea-
bronchial necrosis [23,55, 56, 57,58]. Isolated recurrences in the upper thoracic part are even 
more difficult to treat. They are correlated with less favorable outcomes, limited rescue 
options after initial dCRT and additional side effects including strictures and fistulas, which 
should be treated by an experienced team [59,60].  
In conclusion, in this systematic review we have shown that salvage surgery is a feasible 
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high-risk curative approach in patients with isolated local recurrent or persistent EC after 
dCRT or nCRT alone. In patients with a high probability of complete (R0) resection, the 
prognosis after salvage surgery is more or less equivalent to that after planned surgery 
following nCRT. Careful surveillance is important to define the position of salvage surgery in 
isolated recurrent disease after previous CRT, which can be performed with acceptable results 
































Figure 1. Flowchart of studies assessed during the selection process 





Records identified through 
database searching N=278 
Excluded n=242: 
published before 2007 N=74 
non English language N=34 
non full-text articles N=2 
reviews, case-control studies, 
non-surgical salvage treatment, 
cervical esophageal tumors 
N=132 
Full-text articles assessed for 
eligibility N=36 
Studies according the inclusion 
criteria N=28 
dCRT alone N=25 









dCRT and nCRT n=1 
Full text articles excluded 




Table 1: Clinicopathological characteristics of patients  
Characteristics Total N=1076 ** N (%) dCRT N=954 n (%) nCRT N=110 N (%) 
Sex 
  Male 
  Female 













Mean age/range (years)* 62.4 (49.4-75.4) 62.4 (50.9-73.9) 62.5 (49.5-75.5) 
Histology    
   Adenocarcinoma 
   Squamous cell carcinoma 













Stage (clinical or pathological&) 
 
   I 
   IIA 
   IIB 
   III 
   IVA 
























M1a 11 (1.0) 11 (1.2) 0 (0.0) 
Salvage indication 
   Persistent cancer 
   Recurrent cancer 













R0 after salvage surgery**** 806 (80.7) 725 (87.7) 73 (66.4) 
* Age was not reported in 339 patients in the dCRT group 
**Including the group of Yoo et al. [17] with patients after nCRT (N=2) and dCRT (N=10) 
***The patients in whom it is unclear whether it was persistent or recurrent cancer 
**** Radicality of the operation not reported in 77 patients in the dCRT group 







Table 2a: Characteristics of the studies on salvage surgery after dCRT 
Study Chemotherapy  
regime 




Indication for salvage 
surgery 
Median dose RT (Gy) 
Radiation techniques 
Median time from CRT 





44 60 81.8 44/0 70.4 Persistent 60; IMRT VMAT 3DRT 4 
Farinella  [61] 5-FU + cisplatin 16 61 62.5 14/2 81.3 Persistent or recurrent 57.7 8.4 
Swisher  [23] 5-FU + cisplatin + 
paclitaxel 
21 - - - - Persistent or recurrent 50.4 - 
Okumura  [62] - 10 - - - - Persistent or recurrent 50 - 
Markar  [15] - 308 - 84.1 193/109 87.3 Persistent or recurrent 50 5.5 
Watanabe [9] 5-FU + cisplatin 63 63 92.1 63/0 73.0 Persistent or recurrent 60 - 
Chen  [37] 5-FU +  cisplatin 51 58 84.3 51/0 80.4 Recurrent 54 
IMRT 
8.0 
Sudo  [28] 5-FU +  
cisplatin/taxane 
23 67 91.3 5/18 91.3 Recurrent 50.4; IMRT or proton beam 21 
Akutsu [63] 5-FU + cisplatin 12 62 100 12/0 - Persistent 53.2 - 
Aquino [64] - 18 67.5 88.9 18/0 - Persistent - 7.5 
22 
 
Adenis  [65] 5-FU+cisplatin  16 60 - -/- - Persistent 50.4; Multiple field technique - 
Saeki [66] 5-FU+cisplatin 10 64.7 80.0 10/0 75.0 Persistent or recurrent 60.2; parallel oblique fields or multiple 
fields 
10.3 
Marks  [16] - 65 63 90.8 0/65 90.8 Persistent or recurrent 50 - 
Morita [67] 5-FU+cisplatin 5 61.8 100 5/0 60.0 Persistent or recurrent 60.2; parallel oblique fields or multiple 
fields 
- 
Morita [29] 5-FU + cisplatin 27 63 85.2 -/- 70.4 Persistent or recurrent >60.2; parallel oblique fields or multiple 
fields 
9 
Takeuchi [57] 5-FU + cisplatin 25 61 100 25/0 80.0 Persistent or recurrent 60.2; parallel oblique 
fields or via multiple fields 
3.6 
Ariga [68] 5-FU  +  cisplatin 13 65.5 100 13/0 92.3 Persistent or recurrent 60 8.3 
Miyata [30] 5-FU + cisplatin 33 63.4 84.9 33/0 87.9 Persistent or recurrent 59.8 - 
Tachimori [69] 5-FU + cisplatin 59 63 96.6 59/0 87.7 Persistent or recurrent 60 - 
Chao [58] 5-FU + cisplatin 27 62.4 96.3 27/0 65.4 Persistent or recurrent 30# 2.5 
D'Journo [24] 5-FU + cisplatin 24 59 75.0 16/8 87.5 Persistent or recurrent 62.5 5 
Borghesi [70] 5-FU + cisplatin 10 64.5 60.0 7/3 30.0 Recurrent 57; 1 or 2-phase technique  
Nishimura [71] 5-FU + cisplatin 46 61 91.3 46/0 100 Persistent or recurrent 50 12 
23 
 
Smithers [72] 5-FU + cisplatin 14 66 50.0 5/9 85.7 Persistent or recurrent 60 25 
Oki [73] 5-FU + cisplatin 14 56 92.9 14/0 50.0 Persistent or recurrent 75.2; parallel oblique fields or multiple 
fields 
- 
Abbreviations: CRT= chemoradiotherapy; RT= radiotherapy; dCRT=definitive chemoradiotherapy # Radiation with a total dose of 30 Gy in 2 Gy daily fractions, 5 days a week.  IMRT = intensity-















Table 2b: Characteristics in studies with salvage surgery after nCRT 




Indication of salvage surgery Median RT  
dose (Gy) 
Median time CRT 
to surgery 
(months) 
Taketa [18] 5-FU + 
platinum/taxane 
12 69 100 3/9 100 Recurrent disease   50.4 (39–66) 9.3 
















Median dose RT (Gy) 
Radiation techniques 
Mortali










Lertbutsayanukul 13] 44/0 Persistent 60  
IMRT VMAT 3DRT 
2.3/- 6.8 15.9 
Farinella [61] 14/2 Persistent or 
recurrent 
57.7 0/0 37.5 0 
Swisher [23] - Persistent or 
recurrent 
50.4 -/- 0 0 
Okumura [62] - Persistent or 
recurrent 
50 -/10.0 - - 
Markar [15] 193/109 Persistent or 
recurrent 
50 -/8.4 42.9 13.6 
Watanabe  [9] 63/0 Persistent or 
recurrent 
60 0/0 - - 
Chen [37] 51/0 Recurrent 54 
IMRT 
2.0/- 3.8 0 
 Sudo [28] 5/18 Recurrent 50.4  
IMRT or proton beam 
0/9.0 17.0 0 
Akutsu [63] 12/0 Persistent 53.2 -/- - - 
Aquino [64] 18/0 Persistent - -/- 38.9 0 
26 
 
Adenis [65] -/- Persistent 50.4  
Multiple field technique 
-/- - - 
Saeki [66] 10/0 Persistent or 
recurrent 
60  
2 parallel oblique or multiple 
fields 
-/20.0 50.0 0 
Marks [16] 0/65 Persistent or 
recurrent 
50 3.1/4.6 23.1 0 
Morita [67] 5/0 Persistent or 
recurrent 
60  
2 parallel oblique or multiple 
fields 
0/0 20.0 0 
Morita [29] ?/? Persistent or 
recurrent 
>60   
2 parallel oblique or multiple 
fields 
-/7.4 29.6 0 
Takeuchi [57] 25/0 Persistent or 
recurrent 
60  
2 parallel oblique or multiple 
fields 
0/8.0 44.0 0 
Ariga [68] 13/0 Persistent or 
recurrent 
60 0/- 0 0 
Miyata [30] 33/0 Persistent or 
recurrent 
59.8 3.0/12.0 30.0 24.0 
Tachimori [69] 59/0 Persistent or 
recurrent 
60 -/8.0 32.0 0 
Chao [58] 27/0 Persistent or 
recurrent 
30& -/22.2 27.0 0 







Borghesi [70] 7/3 Recurrent 57 




Nishimura [71] 46/0 Persistent or 
recurrent 
50 9.0/15.0 9.0 2.0 
Smithers [30] 5/9 Persistent or 
recurrent 
60 7.0/7.0 57.0 29.0 
Oki [73] 14/0 Persistent or 
recurrent 
75  
2 parallel oblique fields or 
multiple fields 
0/7.1 21.4 7.1 
Abbreviations: CRT= chemoradiotherapy; RT= radiotherapy; dCRT=definitive chemoradiotherapy & Radiation with a total dose 
of 30 Gy in 200 cGy daily fractions, 5 days a week.  IMRT=Intensity-modulated radiation therapy, VMAT=Volumetric modulated 
arc therapy=VMAT, 3DRT=three-dimensional radiation therapy 
*** Pneumonia, airway congestion, atelectasis, acute lung injury, and acute respiratory distress syndrome 









Table 3: Pooled outcome after salvage according to persistent or recurrent disease 
Outcome Total N=1076 
(persistent and recurrent 
or both)  
% (95% Cl) 
Persistent 
N=482 
% (95% Cl) 
Recurrence 
N=211  









































































1.7 [-0.1; 3.6] 

















0.9 [-0.7; 2.6] 
29 
 
30-day mortality 24 




1.7 [0.0; 3.6] 
 
0.0 [-3.8; 3.8] 


























































Table 4: Outcome of delayed surgery for recurrent or persistent cancer after nCRT  
Outcome dCRT total ** 
% [95% Cl] 









Anastomotic leak 159/853 
18.6 [16.0;21.2] 










0.0,0.0 0.0, 0.0 
Infection 107/853 
12.5 [10.3;14.8] 
1, 8.3 0.0, 0.0 
Hemorrhage 6/853 
0.7 [0.1;1.3] 
0.0, 0.0 0.0, 0.0 
Chylothorax 18/853 
2.1 [1.1;3.1] 
0.0, 0.0 0.0, 0.0 
Conduit necrosis 8/853 
0.9 [0.3;1.6] 





0.0, 0.0 0.0, 0.0 
30-day mortality 26/817 
3.2 [2.0;4.4] 
1, 8.3 2, 2.0 
90-day mortality 73/833 
8.8 [6.8;10.7] 
- 3, 3.1 
















24.4 (19.4; 28.4) 
  












Table 5a: Complications after esophagectomy compared with Esophageal Multimodality Trials 
Trial  Treatment Pulmonary complications % Cardiac complications % Anastomotic leakage % 30-day mortality % 90-day mortality % 
CROSS [3] nCRT + S 46 21 22 4 2 
CALGB 9781 [21] nCRT + S 33 0 8.3 0 - 
Urba [22] nCRT + S - - 14.9 2 - 
RTOG 0246 [23] dCRT + SS - - 4.7 - - 
This study  dCRT + SS 30.2 7.6 18.6 3.2 8.8 










Table 5b: Survival results of salvage surgery compared with Esophageal Multimodality Trials 
Trial  Treatment 3-year OS % 5-years OS % 7-years OS % 
CROSS [3] nCRT+S 60 39 - 
CALGB 9781 [21] nCRT+S 63 39 - 
Urba [22] nCRT+S 30 20 20 
RTOG 0246 [23]  dCRT+SS  44 37 32 
This study  SS after CRT (total group) 
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